{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:29:33Z","timestamp":1776792573926,"version":"3.51.2"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11899-016-0318-1","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T07:27:57Z","timestamp":1461050877000},"page":"185-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas"],"prefix":"10.1007","volume":"11","author":[{"given":"Sally F.","family":"Barrington","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. George","family":"Mikhaeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"318_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25\u201330.","journal-title":"J Nucl Med"},{"key":"318_CR2","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358. International guidelines reporting consensus from major cancer centres and co-operative research groups involved in lymphoma, focusing on the role of PET-CT.","journal-title":"J Clin Oncol"},{"key":"318_CR3","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368. Companion paper to above reference, reporting consensus related to staging and response assessment in lymphoma, introducing new metabolic response categories for PET-CT.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"318_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.12601","volume":"164","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol. 2014;164:315\u201328.","journal-title":"Br J Haematol"},{"key":"318_CR5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","volume":"90","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Villa D, Alzahrani M, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90:1041\u20136.","journal-title":"Am J Hematol"},{"key":"318_CR6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.13831","volume":"172","author":"MJ Bishton","year":"2016","unstructured":"Bishton MJ, Hughes S, Richardson F, et al. Delineating outcomes of patients with diffuse large B cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis. Br J Haematol. 2016;172:246\u201354.","journal-title":"Br J Haematol"},{"key":"318_CR7","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"318_CR8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"318_CR9","doi-asserted-by":"crossref","unstructured":"Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging 2016. doi: 10.1007\/s00259-016-3315-7 . Explored interaction of baseline predictive factors on PET-CT including metabolic tumour volume with early response using Deauville criteria.in 147 consecutive patients treated for DLBCL.","DOI":"10.1007\/s00259-016-3315-7"},{"key":"318_CR10","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329:987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"key":"318_CR11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"318_CR12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342.","journal-title":"Blood"},{"key":"318_CR13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hon.2228","volume":"33","author":"T el-Galaly","year":"2015","unstructured":"el-Galaly T, Cheah CY, Hutchings M, et al. Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP (\u2212like) therapy. Hematol Oncol. 2015;33:181\u2013243 (abstract 211).","journal-title":"Hematol Oncol"},{"key":"318_CR14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"318_CR15","first-page":"1519","volume":"45","author":"R Boellaard","year":"2004","unstructured":"Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519\u201327.","journal-title":"J Nucl Med"},{"key":"318_CR16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"318_CR17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","volume":"91","author":"MK Song","year":"2012","unstructured":"Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET\/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697\u2013703.","journal-title":"Ann Hematol"},{"key":"318_CR18","doi-asserted-by":"crossref","unstructured":"Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, Gallamini A, Siegel BA, Cashen AF, V\u00e9ra P, Tilly H, Versari A, Itti E. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017\u201322.","DOI":"10.1007\/s00259-014-2822-7"},{"key":"318_CR19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2014.59.9373","volume":"33","author":"SF Barrington","year":"2015","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Reply to B. Bennani-Baiti et al., H.J.A. Adams et al., E. Laffon et al., and E.A. Hawkes et al. J Clin Oncol. 2015;33:1221\u20133.","journal-title":"J Clin Oncol"},{"key":"318_CR20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00259-013-2623-4","volume":"41","author":"HJ Adams","year":"2014","unstructured":"Adams HJ, Kwee TC, de Keizer B, et al. FDG PET\/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41:565\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"318_CR21","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","volume":"54","author":"L Berthet","year":"2013","unstructured":"Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54:1244\u201350.","journal-title":"J Nucl Med"},{"key":"318_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","volume":"122","author":"AB Khan","year":"2013","unstructured":"Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61\u20137.","journal-title":"Blood"},{"key":"318_CR23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2967\/jnumed.113.134486","volume":"55","author":"JJ Cerci","year":"2014","unstructured":"Cerci JJ, Gyorke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1591\u20137.","journal-title":"J Nucl Med"},{"key":"318_CR24","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V91.9.3340","volume":"91","author":"R Carr","year":"1998","unstructured":"Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340\u20136.","journal-title":"Blood"},{"key":"318_CR25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00259-008-1021-9","volume":"36","author":"G Paone","year":"2009","unstructured":"Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36:745\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"318_CR26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1600-0609.2006.00644.x","volume":"76","author":"J Campbell","year":"2006","unstructured":"Campbell J, Seymour JF, Matthews J, et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76:473\u201380.","journal-title":"Eur J Haematol"},{"key":"318_CR27","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","volume":"29","author":"LH Sehn","year":"2011","unstructured":"Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452\u20137.","journal-title":"J Clin Oncol"},{"key":"318_CR28","doi-asserted-by":"crossref","unstructured":"Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07). J Clin Oncol. 2015;33:2523\u20139. Prospective study in 138 patients with DLBCL evaluating both interim and EOT PET-CT using standardised methods for PET, confirming role of PET for remission assessment.","DOI":"10.1200\/JCO.2014.58.9846"},{"key":"318_CR29","doi-asserted-by":"crossref","unstructured":"Carr R, Fanti S, Paez D, et al. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1936\u201344. Prospective international study in 327 patients with DLBCL reporting outcomes according to interim and EOT scans showing (i) excellent prognosis of patients with early and late CMR, (ii) good outcomes for \u2018slow responders\u2019 with interim positive and EOT negative scans and (iii) inferior outcomes for patients with early and late positive PETscans. Confirmed role of PET for remission assessment but advised against intensification of treatment on interim PET to avoid overtreatment of patients.","DOI":"10.2967\/jnumed.114.145326"},{"key":"318_CR30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","volume":"52","author":"AF Cashen","year":"2011","unstructured":"Cashen AF, Dehdashti F, Luo J, et al. (18)F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386\u201392.","journal-title":"J Nucl Med"},{"key":"318_CR31","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","volume":"118","author":"IN Micallef","year":"2011","unstructured":"Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118:4053\u201361.","journal-title":"Blood"},{"key":"318_CR32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/10428194.2013.831848","volume":"55","author":"N Nols","year":"2014","unstructured":"Nols N, Mounier N, Bouazza S, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:773\u201380.","journal-title":"Leuk Lymphoma"},{"key":"318_CR33","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","volume":"119","author":"P Pregno","year":"2012","unstructured":"Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066\u201373.","journal-title":"Blood"},{"key":"318_CR34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","volume":"30","author":"V Safar","year":"2012","unstructured":"Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012;30:184\u201390.","journal-title":"J Clin Oncol"},{"key":"318_CR35","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ejca.2010.12.027","volume":"47","author":"D-H Yang","year":"2011","unstructured":"Yang D-H, Min J-J, Song H-C, et al. Prognostic significance of interim (18)F-FDG PET\/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer. 2011;47:1312\u20138.","journal-title":"Eur J Cancer"},{"key":"318_CR36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00277-010-1135-6","volume":"90","author":"C Yoo","year":"2011","unstructured":"Yoo C, Lee DH, Kim JE, et al. Limited role of interim PET\/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90:797\u2013802.","journal-title":"Ann Hematol"},{"key":"318_CR37","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.25579","volume":"117","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Gandolfi L, Broccoli A, et al. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer. 2011;117:1010\u20138.","journal-title":"Cancer"},{"key":"318_CR38","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3109\/10428194.2014.975800","volume":"56","author":"KJ Mylam","year":"2015","unstructured":"Mylam KJ, Kostakoglu L, Hutchings M, et al. (18)F-fluorodeoxyglucose-positron emission tomography\/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic\/US intergroup study. Leuk Lymphoma. 2015;56:2005\u201312.","journal-title":"Leuk Lymphoma"},{"key":"318_CR39","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3109\/10428194.2015.1007506","volume":"56","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Nasta SD, Schuster SJ, et al. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:2579\u201384.","journal-title":"Leuk Lymphoma"},{"key":"318_CR40","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571\u20138.","journal-title":"J Clin Oncol"},{"key":"318_CR41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/annonc\/mdl493","volume":"18","author":"K Strobel","year":"2007","unstructured":"Strobel K, Schaefer NG, Renner C, et al. Cost-effective therapy remission assessment in lymphoma patients using 2- fluorine-18 fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography: is an end of treatment exam necessary in all patients? Ann Oncol. 2007;18:658\u201364.","journal-title":"Ann Oncol"},{"key":"318_CR42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","volume":"15","author":"YL Kasamon","year":"2009","unstructured":"Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009;15:242\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"318_CR43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.13036","volume":"167","author":"E Pardal","year":"2014","unstructured":"Pardal E, Coronado M, Martin A, et al. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014;167:327\u201336.","journal-title":"Br J Haematol"},{"key":"318_CR44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjh.13389","volume":"170","author":"LJ Swinnen","year":"2015","unstructured":"Swinnen LJ, Li H, Quon A, et al. Response-adapted therapy for aggressive non-Hodgkin\u2019s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015;170:56\u201365.","journal-title":"Br J Haematol"},{"key":"318_CR45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V124.21.391.391","volume":"124","author":"U Duehrsen","year":"2014","unstructured":"Duehrsen U, H\u00fcttmann A, M\u00fcller S, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas\u2014a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood. 2014;124:391.","journal-title":"Blood"},{"key":"318_CR46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V124.21.392.392","volume":"124","author":"LH Sehn","year":"2014","unstructured":"Sehn LH, Hardy ELG, Gill KK, et al. Phase 2 trial of interim pet scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood. 2014;124:392.","journal-title":"Blood"},{"key":"318_CR47","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.23861","volume":"113","author":"E Derenzini","year":"2008","unstructured":"Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer. 2008;113:2496\u2013503.","journal-title":"Cancer"},{"key":"318_CR48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/bmt.2010.130","volume":"46","author":"V Roland","year":"2011","unstructured":"Roland V, Bodet-Milin C, Moreau A, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant. 2011;46:393\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"318_CR49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bmt.2012.168","volume":"48","author":"S Akhtar","year":"2013","unstructured":"Akhtar S, Al-Sugair AS, Abouzied M, et al. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT. Bone Marrow Transplant. 2013;48:551\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"318_CR50","doi-asserted-by":"crossref","unstructured":"Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125:2579\u201381. Retrospective review of 126 patients with B-NHL undergoing ASCT showing Deauville scores to be predictive of treatment outcomes.","DOI":"10.1182\/blood-2014-10-606939"},{"key":"318_CR51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","volume":"8","author":"A Janikova","year":"2008","unstructured":"Janikova A, Bolcak K, Pavlik T, et al. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma. 2008;8:287\u201393.","journal-title":"Clin Lymphoma Myeloma"},{"key":"318_CR52","doi-asserted-by":"crossref","unstructured":"Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24:2108\u201312. Largest study reporting PET for staging FL in 124 patients in a randomised trial, demonstrating PET is more sensitive than CT for nodal and extranodal disease. Confirmed reports that upstaging by PET can change management in significant proportion of patients with limited stage on CT but that PET misses bone marrow involvement in FL.","DOI":"10.1093\/annonc\/mdt137"},{"key":"318_CR53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00259-008-0958-z","volume":"36","author":"AM Scott","year":"2009","unstructured":"Scott AM, Gunawardana DH, Wong J, et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:347\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"318_CR54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","volume":"71","author":"A Wirth","year":"2008","unstructured":"Wirth A, Foo M, Seymour JF, et al. Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2008;71:213\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"318_CR55","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","volume":"329","author":"P Solal-Celigny","year":"1993","unstructured":"Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. N Engl J Med. 1993;329:1608\u201314.","journal-title":"N Engl J Med"},{"key":"318_CR56","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"318_CR57","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","volume":"28","author":"W Hiddemann","year":"2014","unstructured":"Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28:1388\u201395.","journal-title":"Leukemia"},{"key":"318_CR58","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","volume":"20","author":"A Noy","year":"2009","unstructured":"Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508\u201312.","journal-title":"Ann Oncol"},{"key":"318_CR59","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","volume":"23","author":"H Schoder","year":"2005","unstructured":"Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:4643\u201351.","journal-title":"J Clin Oncol"},{"key":"318_CR60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"318_CR61","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"318_CR62","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012;30:4317\u201322.","journal-title":"J Clin Oncol"},{"key":"318_CR63","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","volume":"25","author":"S Luminari","year":"2014","unstructured":"Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25:442\u20137.","journal-title":"Ann Oncol"},{"key":"318_CR64","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Hematol. 2014;1:e17\u201327. Pooled analysis of three multicentre studies with 246 patients with FL. Demonstrated PET to be superior to CT-based response assessment after induction chemoimmunotherapy. PET was an independent predictor of PFS compared with CT response and FLIPI. Median PFS was 74\u00a0months for patients with CMR on PET but only 16.9\u00a0months for patients without CMR.","journal-title":"Lancet Hematol"},{"key":"318_CR65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00259-014-2896-2","volume":"42","author":"M Alcantara","year":"2015","unstructured":"Alcantara M, Dupuis J, Mareschal S, et al. PET\/CT before autologous stem cell transplantation predicts outcome in refractory\/relapsed follicular lymphoma. Eur J Nucl Med Mol Imaging. 2015;42:215\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0318-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-016-0318-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0318-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T21:09:49Z","timestamp":1600463389000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-016-0318-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s11899-016-0318-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}